Gerresheimer shares tumbled 14% in German trading after Germany's financial watchdog BaFin expanded its investigation into the medical products maker's financial reporting practices. The expanded probe adds to mounting pressure on the company, which has already seen its stock decline roughly 42% year to date following a 61% drop in 2025.

BaFin is now examining Gerresheimer's 2024 financial statements for potential issues including misstated lease liabilities and failure to recognize impairments in assets within the Advanced Technologies unit. The regulator has also opened a separate audit into the company's 2025 half-year report, citing concerns about outdated risk disclosures, missing impairment charges, and misstated bill-and-hold revenue.

The accounting troubles come as Gerresheimer postponed its fiscal 2024 results, citing ongoing probes. The company faces a weaker financial outlook and recent leadership changes, including the departure of former CEO Dietmar Siemssen and former CFO Bernd Metzner. UBS analysts noted the new 2025 audit reveals errors in risk assessment, impairment losses, and revenue recognition methods.